Reata Pharmaceuticals Inc buy Heureka
Summary
This prediction ended on 04.02.20 with a price of €220.00. The BUY prediction by Heureka finished with a performance of 17.02%. Heureka has 50% into this predictionReata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on identifying, developing, and commercializing novel therapeutics for patients with severe and life-threatening diseases. The company's primary business areas include drug discovery and development in fields such as cardiovascular, fibrotic, mitochondrial, and neurodegenerative diseases. With a strong emphasis on research and innovation, Reata Pharmaceuticals seeks to deliver cutting-edge treatments that address unmet medical needs, improve patient outcomes, and significantly impact the lives of those suffering from rare and debilitating conditions. As a publicly traded company, Reata Pharmaceuticals is listed on the NASDAQ stock exchange under the ticker symbol "RETA."
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Reata Pharmaceuticals Inc | - | - | - | - |
iShares Core DAX® | -0.383% | 5.404% | 14.198% | 21.243% |
iShares Nasdaq 100 | 1.248% | 6.732% | 34.022% | 59.234% |
iShares Nikkei 225® | 0.525% | 1.840% | 10.062% | 9.459% |
iShares S&P 500 | 0.640% | 4.710% | 27.309% | 50.394% |
Comments by Heureka for this prediction
In the thread Reata Pharmaceuticals Inc diskutieren
In the thread Trading Reata Pharmaceuticals Inc